Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesinaact in NASH and Type 2 Diabetes
NCT03950505Phase 4Unknown
- Sponsor
- Yonsei University
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of alogliptin in Nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM), sponsored by Yonsei University. Primary endpoint: Degree of liver steatosis at 24 weeks. Status: unknown.
02
Drugs
alogliptin
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03950505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950505.